Categories: News

Sandstone Easydrip Plus Pen Needles Debut in Turkey — PatentProtected Hexagonal Hub for Comfort and Control

Large‑platform hexagonal hub (Hextra Tech) offers superior stability and ease of grip; ISO 13485 & CE certified; launched by a leading regional diabetes distributor and 4,000+ pharmacies

- Advertisement -

ISTANBUL, Oct. 11, 2025 /PRNewswire/ — Sandstone Medical — a SteriLance Medical sub‑brand focused on diabetes self‑injection — today announced the introduction of its Easydrip™ Plus pen needles into the Turkish market through a leading regional diabetes distributor with a nationwide pharmacy network. The launch is already unlocking interest from neighbouring Middle‑East markets.

- Advertisement -

Key advantages

- Advertisement -
  • Hextra Tech hexagonal hub — a broad, six‑facet platform that helps patients keep the pen steady during insertion, reducing wobble, bruising and needle bending versus conventional narrow‑hub pen needles.
  • Greater dosing confidence — the enlarged contact surface promotes a consistent injection angle, supporting accurate sub‑cutaneous delivery.
  • Thin‑wall cannula with silicone lubrication — minimises penetration force and shortens injection time for a gentler daily routine.

Market relevance

- Advertisement -

As the first pen needle with a patent‑protected hexagonal hub available in Turkey, Easydrip™ Plus is already attracting interest from neighbouring countries and sets a practical alternative between premium global brands and low‑end generics.

- Advertisement -

Availability & next steps

- Advertisement -
  • Current channel: nationwide community pharmacies, often bundled with blood‑glucose meters.
  • Planned expansion: influencer‑driven digital campaigns and e‑commerce to reach online‑first consumers across Turkey and neighbouring states.

Certifications

- Advertisement -

Easydrip™ Plus is manufactured under a strict ISO 13485 quality system and holds CE Declaration of Conformity, meeting international safety and performance standards.

- Advertisement -

Brand Relationship

- Advertisement -

Sandstone Medical is SteriLance Medical’s diabetes‑care brand focused on self‑injection. Easydrip™ products are developed and marketed by Sandstone, with SteriLance providing manufacturing and quality systems under ISO 13485.

- Advertisement -

About Sandstone and SteriLance Medical

- Advertisement -

Sandstone designs patient‑centric solutions that make daily injections steadier and more comfortable. Founded in 1993, SteriLance Medical is a global innovator in blood‑sampling and injection solutions with 200+ patents and distribution in 50+ countries.
More information: en.sandstonemed.com | en.sterilance.com 
Media & distribution enquiries: smu@sterilance.com 

- Advertisement -

Photo – https://mma.prnewswire.com/media/2794048/Bridging_gap_premium_low_end_options__advanced_large_platform_design__ISO_13485.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/sandstone-easydrip-plus-pen-needles-debut-in-turkey–patentprotected-hexagonal-hub-for-comfort-and-control-302581334.html

- Advertisement -

Recent Posts

More Than 60 Nations Unite as IIHM Launches GAIHEC, the World’s First Global AI Hospitality Education Council

On World AI Day, IIHM unveils a global movement to ensure Artificial Intelligence strengthens hospitality's…

4 hours ago

Singtel Receives Four Frost & Sullivan 2026 Recognitions for Leadership in Enterprise Connectivity, Cybersecurity, and Digital Transformation

The recognitions highlight Singtel's leadership in secure connectivity, network transformation, IoT innovation, and cybersecurity, delivering…

18 hours ago

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

July 18, 2026 15:15 ET  | Source: 4D Molecular Therapeutics, Inc. After a single intravitreal…

19 hours ago

Immuneering Corporation Announces Grants of Inducement Awards

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical…

19 hours ago

FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

Silver Spring, MD, July 17, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration approved Lipfendra…

19 hours ago